Microfluidics News Microfluidics News

  • Cambridge researchers developing self-healing concrete
    by Gina Mikalauskaite on 30th November 2018 at 10:29 am

      Researchers from the University of Cambridge are using microencapsulation technologies developed by Dolomite Microfluidics to create self-healing construction materials. The Geotechnical and Environmental Research Group are developing microcapsules containing ‘healing’ agents – such as exoxy or polyurethane – which can be added to building materials to allow self-repair of small cracks which develop over... The post Cambridge researchers developing self-healing concrete appeared first on Dolomite Microfluidics. […]

  • Dolomite Microfluidics highlights of MicroTAS 2018
    by Gina Mikalauskaite on 29th November 2018 at 12:27 pm

      Dolomite Microfluidics attended our biggest event of the year in November – MicroTAS! Here’s the lowdown on our time spent in Kaohsiung, Taiwan…   Our booth was set up and ready for action when the doors opened on Sunday 11th and more than 900 worldwide scientists and professionals flooded in! This year’s venue was an... The post Dolomite Microfluidics highlights of MicroTAS 2018 appeared first on Dolomite Microfluidics. […]

  • Labcyte Introduces the Echo 650 and 655 Liquid Handlers
    by Labcyte Inc. on 16th October 2018 at 12:00 am

    Labcyte Inc. today launched the Echo® 650 and 655 Liquid Handlers, which employ the unique capabilities of acoustic droplet ejection (ADE) technology with 2.5 nanoliter transfers. The 650 and 655 microplate-based systems include features to improve usability that were first made available in the recently launched 650T and 655T tube and microplate-enabled products. The 650 and 655 systems, which will be offered in addition to the Echo 500-series Liquid Handlers, are upgradeable to support transfers from Echo qualified acoustic sample tubes. Launched at the Society of Laboratory and Screening (SLAS) meeting in February and winner of the SLAS 2018 New Product Award, the Echo 650T and 655T Liquid Handlers incorporated several new features in addition to the ability to transfer liquids from Echo Qualified acoustic tubes. “We recognize that many of our users who work with our 550 or 555 systems are not ready to incorporate acoustic tubes into their workflows but may value the other advancements offered in our 650T and 655T systems,” said Chris Grimley, Vice President of Marketing at Labcyte. “We decided to make those features available to them in these new models, and at the same time provide them the ability to add the tube transfer capability when they are ready for it.” The new Echo 650 and 655 Liquid Handlers are based on the company’s patented acoustic droplet ejection technology, which uses the gentle energy of sound waves to move liquids at nanoliter resolution with superior precision and accuracy. The technology does not contact the liquid in any way, avoiding the risk for sample loss, carryover or cross-contamination. It also enables assay miniaturization with reliable fluid transfers at volumes as low as 2.5 nanoliters – saving time and cost, all while improving data quality. Echo Liquid Handlers are relied on throughout life science research to revolutionize workflows in drug discovery, genomics, synthetic biology, and precision medicine. The 600-series Echo systems feature an improved fluidics system with a simplified maintenance procedure. In addition, the new fluidics system no longer requires vacuum assist, resulting in quieter operation. Other improvements include an automated plate height adjustment, eliminating the need for physical microplate inserts, and simplifying robotic integration. These new features improve the overall usability of this next offering of Echo systems and result in less maintenance requirements. “Echo Acoustic Liquid Handlers have re-shaped life sciences by providing highly accurate, fully automated, touchless, low-volume dispensing of fluids,” said Mark Fischer-Colbrie, President and Chief Executive Officer at Labcyte. “With their high transfer accuracy and precision down to nanoliter volumes and with rapid any-well to any-well transfer capabilities, Echo Liquid Handlers have long been integral to state-of-art sample management and high-throughput screening solutions and hundreds of other applications. We are excited to introduce these product line extensions that offer the latest advancements to the broader community.” The company will be featuring the new systems at the upcoming SLAS Americas Sample Management Symposium in Boston. About Labcyte Inc. Labcyte, a global biotechnology tools company headquartered in San Jose, California, is revolutionizing liquid handling. Echo® Liquid Handlers use sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organizations, and academic institutions. Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalized medicine. Labcyte has 63 U.S. patents and others internationally. For more information, visit www.labcyte.com. PR Contact for Labcyte Inc: Nicole Litchfield Bioscribe, Inc. (415) 793-6468 nicole@bioscribe.com […]

  • Arzeda Leverages Scalable Synthetic Biology Resources to Drive Computational Protein Design Platform
    by Labcyte Inc. on 2nd October 2018 at 12:00 am

    Arzeda, the Protein Design Company™, Twist Bioscience Corporation, TeselaGen Biotechnology Inc. and Labcyte Inc. have partnered to build a state-of-the-art DNA assembly platform to significantly reduce the time and cost required to build genes encoding Arzeda’s designed proteins. The customized platform supports the high-throughput screening of Arzeda’s computationally-designed proteins and enzymes. Arzeda will receive high-quality, linear DNA fragments from Twist Bioscience that will be used to assemble large collections of plasmids encoding Arzeda-designed proteins. Twist Bioscience will provide the DNA fragments in Labcyte acoustic-compatible plates for use with the Echo® Liquid Handler from Labcyte, which will reduce cost and significantly speed Arzeda’s ability to test its proteins. The Echo system will automatically follow instructions generated by TeselaGen’s laboratory automation software to build large plasmid collections used in downstream testing. “By adding the Echo Liquid Handler to the arsenal, we will build on our successful partnerships with Twist Bioscience and TeselaGen to reduce the time and cost of our DNA construction process by more than 10x,” said Alexandre Zanghellini, Ph.D., CEO of Arzeda. “By collaborating with these world-class leaders in DNA synthesis, liquid handling and automation, Arzeda’s Genetic Design-Build team will be able to construct thousands of very large genes per week, which will bring significant value to our commercial partners and our own internal projects,” he continued. “Computational protein design is transformative for all biotechnology. Its reach includes designing novel enzymes for the sustainable manufacturing of chemicals and materials, improving existing biologics and developing new sensors for diagnostics. To deliver on this potential, Arzeda requires tight integration between large-scale computing and the rapid build-out and testing of massive collections of proteins designed using our proprietary software,” said Zanghellini. Twist Bioscience has been Arzeda’s primary supplier of clonal, fully-built DNA for nearly two years and will now additionally provide large amounts of linear DNA fragments. “In this expanded partnership, we will provide the highest quality linear DNA in large-scale quantities to enable Arzeda to continue innovating its computational protein design functionality,” said Emily M. Leproust, Ph.D., CEO of Twist. Twist Bioscience has also enabled its API to integrate with TeselaGen’s BUILD app, which automates DNA assembly design, so in addition to seamlessly ordering DNA from Twist Bioscience, Arzeda can also construct much longer segments of DNA. TeselaGen’s Synthetic Evolution™ platform has been used by Arzeda for the last three years to generate protocols for DNA design via the TeselaGen DESIGN module, and has now been extended through a new BUILD module to generate instructions for laboratory robots such as the Echo Liquid Handler from Labcyte. Arzeda has already deployed TeselaGen’s BUILD module and plans to expand the relationship. “The platform we are building with Arzeda significantly accelerates workflows by optimizing information flow. It has been an exciting collaboration that continues to expand as we move downstream into the TEST and EVOLVE modules for analytic data acquisition and analysis,” said Michael Fero, Ph.D., CEO of TeselaGen. “The Echo Liquid Handler speeds up complex laboratory workflows and dramatically reduces running costs by miniaturizing reactions containing precious reagents," said Mark Fischer-Colbrie, CEO of Labcyte. “Through this partnership, we will ensure the seamless integration of our acoustic liquid handling technology with the Arzeda platform to rapidly and reliably build and test novel proteins.” About Labcyte Inc. Labcyte, a global biotechnology tools company headquartered in San Jose, California, is revolutionizing liquid handling. Echo® Liquid Handlers use sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organizations, and academic institutions. Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalized medicine. Labcyte has 63 U.S. patents and others internationally. For more information, visit www.labcyte.com. About TeselaGen TeselaGen is building a deep learning-powered solution for rapid, precise and accurate DNA making and modification. TeselaGen's cloud-based enterprise platform bridges the gap between good ideas and the realization of valuable products like vaccines, biologic medicines, and sustainably sourced chemicals. Positioned at the intersection of design and biology, TeselaGen is applying forward engineering approaches to design, build and test in the biological realm. TeselaGen is privately held and is based in the software hub of San Francisco, CA. Follow TeselaGen on Twitter, and learn more at www.teselagen.com. About Twist Bioscience Corporation We are a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. We are leveraging our unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next generation sample (NGS) preparation, and antibody libraries for drug discovery and development. We are also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. We make products for use across many industries including healthcare, industrial chemicals, agriculture and academic research. For more information about our products and services, please visit www.twistbioscience.com. Twist Bioscience is on Twitter. Sign up to follow our Twitter feed @TwistBioscience at https://twitter.com/TwistBioscience. About Arzeda Since 2008 Arzeda, The Protein Design Company™, has harnessed the power of computational protein design to build novel enzymes and discover new pathways that enable cost effective, sustainable production of value-added specialty chemicals and ingredients. In partnership with Fortune 500 companies and industrial leaders, the company has developed a portfolio of proteins that increase the efficiency, robustness and diversity of biological processes. Our proprietary pathway design software unlocks new opportunities for specialty chemicals, advanced materials and health and nutrition products that would otherwise be impossible to exploit. More information is available at www.arzeda.com. Arzeda is on Twitter. Sign up to follow our Twitter feed @ArzedaCo at https://twitter.com/ArzedaCo. PR Contact for Arzeda (206) 402-6506 info@arzeda.com PR Contact for Twist Bioscience Angela Bitting (925) 202-6211 abitting@twistbioscience.com PR Contact for Labcyte Inc: Nicole Litchfield Bioscribe, Inc. (415) 793-6468 nicole@bioscribe.com PR Contact for Teselagen Michael Fero, Ph.D. Mike.fero@teselagen.com […]

  • Labcyte to Support GP-write Project Under New Agreement with Center of Excellence for Engineering Biology
    by Labcyte Inc. on 17th July 2018 at 12:00 am

    Labcyte Inc. today announced an agreement with the Center for Excellence in Engineering Biology (CEEB), an independent nonprofit that is managing initial planning and coordination of efforts for the Genome Project-write (GP-write). As part of the agreement, Labcyte will provide preferred pricing and in-kind support to researchers at qualified laboratories that are affiliated with and contributing to the mission and goals of GP-write. Additionally, Labcyte will provide selected researchers with early access to certain new products it develops. GP-write is an open, international scientific research project led by a multi-disciplinary group of scientific leaders who expect to oversee a reduction in the costs of engineering and testing of large genomes in cell lines by more than 1,000-fold within 10 years. Thus far, nearly 200 scientists affiliated with more than 100 organizations from 15 countries are involved in the project. Additionally, GP-write is developing new technologies, an ethical framework for genome-scale engineering and transformative medical applications. Labcyte is one of the founding members of the GP-write Industry Advisory Board, which is charged with developing complete workflow solutions for laboratories participating in the project. With its revolutionary acoustic liquid handling technology that enables the rapid synthesis and quality control of DNA assemblies, the company is a leader in enabling key steps for synthetic biology applications. Traditional DNA assembly methods require reactions of 10 to 20 microliters per well. Echo® Liquid Handlers from Labcyte reduce reaction volumes by up to 100x, enabling scientists to achieve drastically reduced reagent costs, along with faster, more accurate liquid transfers without the risk of contact-induced volume loss or contamination associated with tip-based instruments. Market-leading synthetic biology companies use Echo Liquid Handlers to automate gene synthesis with higher throughput and lower cost than they could with pipette-based systems. More information about the company’s solutions for synthetic biology can be found here. Labcyte Chief Executive Officer Mark Fischer-Colbrie commented, “Synthetic biology is another rapidly growing application of our touchless acoustic liquid handling systems which are broadly used in workflows ranging from drug discovery to personalized medicine to diagnostics, all of which achieve lower costs, faster assembly times and less reagent consumption. We are delighted to partner with GP-write and to support researchers working in this field. We look forward to seeing how we can innovate and push discoveries ahead faster together.” “Labcyte is an ideal partner for this important and far-reaching project, which aims to facilitate the use of biological engineering to address many global challenges facing humanity,” said Nancy J. Kelley, organizer and lead executive of the CEEB. “Labcyte’s revolutionary technology is uniquely suited to accelerate the work of the interdisciplinary research teams working around the globe that have engaged with GP-write.” About GP-write The GP-write Leadership Group includes Jef Boeke, Founding Director, Institute for Systems Genetics, NYU Langone Health; George Church, Core Faculty, Wyss Institute for Biologically Inspired Engineering, Harvard Medical School; Andrew Hessel, CEO, Humane Genomics, Inc. and Nancy J Kelley, President and CEO, Nancy J Kelley & Associates. GP-write is being implemented through the Center of Excellence for Engineering Biology, which supports the formation and work of multi-institutional and interdisciplinary research teams working in a highly integrated fashion, responsive to and engaged with a broad public outreach. To date, nearly 200 scientists, affiliated with more than 100 institutions/companies in 15 countries, are participating in GP-write. For more information about GP-write and the Center of Excellence for Engineering Biology, visit www.engineeringbiologycenter.org. About Labcyte Inc. Labcyte, a global biotechnology tools company headquartered in San Jose, California, is revolutionizing liquid handling. Echo® liquid handling systems use sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organizations, and academic institutions. Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalized medicine. Labcyte has 62 U.S. patents and others internationally. For more information, visit www.labcyte.com. PR Contact for Labcyte Inc: Nicole Litchfield Bioscribe, Inc. 415-793-6468 nicole@bioscribe.com PR Contact for GP-write: Carol Miller 202-306-0130 carolmiller100@gmail.com […]

University of Toronto partners National Research Council to create a national research hub for microfluidics.

Shrinking entire medical labs onto chips with the help of nanotechnology